Camrelizumab (SHR-1210) (INN) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma. This drug is being developed by Jiangsu HengRui Medicine Co., Ltd. , camrelizumab is undergoing Phase II/III trials. References Monoclonal antibodies